As with any medication, its important to weigh the potential benefits against the risks and consider each persons individual situation
Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Most Doubt the Trump Administration Will Lower Drug Costs for People Like Them, Though Three-Fourths of Republicans Expect It Will About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds
Pharmacy and claims data indicate several-fold growth in prescriptions for semaglutide and tirzepatide during this period, with the highest uptake among middle-aged adults and those with private insurance
Importantly, these medications are not recommended for patients with severe gastrointestinal disease, including gastroparesis, due to their effects on gastric emptying
